Brought to you by 
Checkmate completes $27mm Series B round
16 Jun 2017
Executive Summary
Checkmate Pharmaceuticals Inc. (oncology) raised $27mm in its Series B round from new investor F-Prime Capital Partners (lead), along with returning backers Sofinnova and venBio. Proceeds will fund ongoing studies of CMP001, a CpG-A oligonucleotide therapeutic in Phase Ib trials in combination with pembrolizumab for melanoma, and will also support development of the candidate in additional potential indications.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Checkmate completes $27mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice